Department of Radiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yi Shan Road, Shanghai, 200233, P. R. China.
Department of Chemical Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK.
Adv Healthc Mater. 2022 Oct;11(19):e2201265. doi: 10.1002/adhm.202201265. Epub 2022 Jul 31.
The development of a fibrinolytic system with long circulation time, high thrombus targeting, efficient thrombus penetration, effective thrombolysis, and minimal hemorrhagic risk remains a major challenge. Herein, inspired by fibrinogen binding to activated platelets in thrombosis, this article reports a fibrinogen-mimicking, activated-platelet-sensitive nanocoacervate to enhance thrombus penetration of tissue plasminogen activator (tPA) for targeted thrombolytic therapy. This biomimetic nanothrombolytic system, denoted as RGD-Chi@tPA, is constructed by "one-pot" coacervation through electrostatic interactions between positively charged arginine-glycine-aspartic acid (RGD)-grafted chitosan (RGD-Chi) and negatively charged tPA. Flow cytometry and confocal laser scanning microscopy measurements show targeting of RGD-Chi@tPA to activated platelets. Controlled tPA release triggered by activated platelets at a thrombus site is demonstrated. Its targeted fibrinolytic and thrombolytic activities are measured in in vitro models. The pharmacokinetic profiles show that RGD-Chi@tPA can significantly prolong circulation time compared to free tPA. In a mouse tail thrombus model, RGD-Chi@tPA displays efficient thrombus targeting and penetration, enabling a complete vascular recanalization as confirmed by the fluorescence imaging, histochemical assay, and laser speckle contrast imager. Consequently, RGD-Chi@tPA induces a substantial enhancement in thrombolysis with minimal hemorrhagic risk compared to free tPA. This simple, effective, and safe platform holds great promise for the development of thrombolytic nanomedicines.
开发一种具有长循环时间、高血栓靶向性、高效血栓穿透性、有效溶栓和最小出血风险的纤维蛋白溶解系统仍然是一个主要挑战。受纤维蛋白原与血栓形成中的活化血小板结合的启发,本文报道了一种纤维蛋白原模拟的、活化血小板敏感的纳米凝聚体,以增强组织型纤溶酶原激活剂(tPA)的血栓穿透性,用于靶向溶栓治疗。这种仿生纳米溶栓系统,命名为 RGD-Chi@tPA,是通过带正电荷的精氨酸-甘氨酸-天冬氨酸(RGD)接枝壳聚糖(RGD-Chi)和带负电荷的 tPA 之间的静电相互作用,通过“一锅法”凝聚而成。流式细胞术和共聚焦激光扫描显微镜测量显示 RGD-Chi@tPA 靶向活化血小板。证明了在血栓部位由活化血小板触发的受控 tPA 释放。在体外模型中测量其靶向纤维蛋白溶解和溶栓活性。药代动力学研究表明,与游离 tPA 相比,RGD-Chi@tPA 能显著延长循环时间。在小鼠尾巴血栓模型中,RGD-Chi@tPA 显示出高效的血栓靶向性和穿透性,通过荧光成像、组织化学分析和激光散斑对比成像证实了完全的血管再通。因此,与游离 tPA 相比,RGD-Chi@tPA 诱导的溶栓作用显著增强,出血风险最小。这种简单、有效和安全的平台为溶栓纳米药物的发展提供了巨大的前景。